Table 2 Clinical efficacy and improvements in CNS-related symptoms in the study population
BM cohort (N = 12) N(%) | LM cohort (N = 16) N(%) | |
|---|---|---|
Median follow up duration | ||
Month (range) | 6.3 (1.5–15.1) | 7.8 (1.9–15.4) |
Median iPFS, months (95%CI) | 3.6 (1.435–5.705) | 4.3 (2.094–6.486) |
Median PFS, months (95%CI) | 2.3 (0.000–4.677) | 4.3 (2.094–6.486) |
Overall best intracranial response | ||
ORR | 2 (22.2) | – |
DCR | 8 (88.9) | – |
CR | 0 (0.0) | – |
PR | 2 (22.2) | – |
SD | 6 (66.7) | – |
PD | 1 (11.1) | – |
Not evaluable | 3 (25.0) | – |
Overall best extracranial response | ||
ORR | 1 (8.3) | 1 (6.3) |
DCR | 4 (33.3) | 7 (43.8) |
CR | 0 (0.0) | 0 (0.0) |
PR | 1 (8.3) | 1 (6.3) |
SD | 3 (25.0) | 6 (37.5) |
PD | 4 (33.3) | 1 (6.3) |
Not evaluable | 4 (33.3) | 8 (50.0) |
Number of OS events (%) | 4 (33.3) | 7 (43.8) |
Number of PFS events (%) | 12 (100.0) | 9 (56.3) |
Number of iPFS events (%) | 10 (83.3) | 9 (56.3) |
Improvement in CNS-related symptoms | ||
Improvement | 3 (100.0) | 8 (53.3) |
No improvement | 0 (0.0) | 4 (26.7) |
Deterioration in symptoms | 0 (0.0) | 3 (20.0) |